Nubeqa (Darolutamide) Patent Expiration, LOE Window & CMS Spending

Nubeqa (Darolutamide) by Bayer: FDA Orange Book core substance LOE 2038-02-27 (last listed 2042-06-17), 0 AB generics, $1.07B 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayN212099 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-02-27
Last Listed Patent or Exclusivity Date2042-06-17
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.07B
2024 Medicare Part D Spend$998.1M
2024 Medicaid Spend$73.3M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 17.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.